SCHEDULE: Vanguard Group Divests Esperion Therapeutics Stake

The Vanguard Group reported a 0% beneficial ownership in Esperion Therapeutics Inc. common stock following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Esperion Therapeutics Inc.
• The Vanguard Group now beneficially owns 0.00 shares of Esperion Therapeutics Inc. common stock, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately, and The Vanguard Group, Inc. no longer consolidates these holdings for its own reporting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Esperion Therapeutics, as the change in beneficial ownership by The Vanguard Group is due to an internal corporate realignment rather than a direct divestment based on Esperion's performance.

Negatives

• The Vanguard Group, a major institutional investor, now reports 0% beneficial ownership in Esperion Therapeutics Inc. common stock, which could be perceived negatively by some investors, despite the explanation of an internal realignment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Esperion Therapeutics Inc.

Industry Context

StockSavvy.ai notes that institutional investor filings like Schedule 13G provide transparency into significant ownership changes. While The Vanguard Group's 0% beneficial ownership in Esperion Therapeutics is due to an internal realignment, such changes can sometimes influence market perception, especially if not clearly understood. This disaggregation of reporting is a common practice for large asset managers to comply with regulatory guidance.

Stakeholder Impact

• Shareholders of Esperion Therapeutics Inc. may note the change in reported institutional ownership, which could lead to minor shifts in market perception or trading activity, though the underlying investment by Vanguard's various entities may still exist, just reported differently.

Key Dates

Recommendation

The filing indicates an administrative change in how The Vanguard Group reports its beneficial ownership due to an internal realignment, rather than a strategic divestment based on Esperion Therapeutics' fundamentals. Therefore, it does not provide a strong signal for a buy or sell recommendation, suggesting a 'hold' position for existing investors.

Keywords

Esperion Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser, Shareholding Change